Isaac Eliaz, MD, MS, LAc, has been in clinical practice for over 30 years with a focus on treating cancer and chronic degenerative conditions. In addition to his clinical work, his activities include extensive research and educational endeavors in collaboration with leading academic and research institutions in the US and world-wide. He has coauthored numerous peer reviewed papers and is a frequent CME lecturer, sharing his research findings at international scientific conferences around the world. In addition, he writes and speaks regularly to educate lay audiences in healthy self-care and preventative practices.
Dr. Eliaz is well-known for his work in the development of PectaSol-C Modified Citrus Pectin, a compound that inhibits galectin-3, an inflammatory protein shown to drive chronic diseases in vital organs (cardiac, kidney, liver, lung), as well as cancer proliferation and metastasis. 27 scientific papers have been published evaluating the use of PectaSol-C, demonstrating its ability to inhibit inflammation and fibrosis in multiple organs and inhibit cancer proliferation, angiogenesis, adhesion and metastasis.
He is currently developing a medical device for the removal of galectin-3 from the circulation, purposed to provide a novel treatment for conditions such as chronic kidney disease (CKD), in which no effective therapies exist. Preliminary research results suggest that the device has broad clinical application potential for treatment of acute and chronic inflammatory and fibrotic conditions, and in cancer immunotherapy.